Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Probability of Positive ROI with ATE - Jan 22. Market Close

<< Previous

Bullboard Posts

Next >>

Comment by Layth1990on Jan 22, 2021 5:04pm

260 Views

Post# 32362337

RE:Probability of Positive ROI with ATE - Jan 22. Market Close

many factors are keeping stock price down. covid is one of them as it might affect phase 3 and cause delay. 2nd, we don't have enough cash and we still don't have any partners.3rd, investors don't like dilution. dilution will happen regardless in my openion.

what is the worst thing could happen ?
no partners and phase 3 will be postponed. 2022 we might see phase 3 ? that is okay and i'm sure sp will hit much more than 8.9cad (like during phase 2).

<< Previous

Bullboard Posts

Next >>

HPQ Silicon updates shareholders on Fumed Silica Reactor developments